Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
STM, together with colleagues at the Department of Chemistry of the University of Liverpool (UoL), The University Hospital Bonn, the University of Buea in Cameroon and the Japanese pharmaceutical company Eisai, are developing a new drug to target the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis. These are both debilitating infections that affect more than 150 million people globally. The drug candidate, AWZ1066S is funded to enter a Phase II clinical trial in 2023 and the design of the trial requires the supply of Albendazole and an Albendazole placebo for use in the clinical trial.
Additional information: The contracting authority considers that this contract may be suitable for economic operators that are small or medium enterprises (SMEs). However, any selection of tenderers will be based solely on the criteria set out for the procurement.
No supplier information available.